Amid the COVID-19 crisis, the United States Continuous Glucose Monitoring (CGM) was valued at $2,830 Million in 2021 and is expected to grow at a CAGR of 11.5% in the forecast period, to reach $6,000
Founded year: | Not set |
Funding rounds: | Not set |
Total funding amount: | Not set |